Kidney Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Adjuvant Everolimus for Resected Kidney Cancer
(Posted: 06/12/2012) - In this clinical trial, patients with renal cell cancer who have undergone partial or complete nephrectomy will be randomly assigned to take everolimus tablets or matching placebo tablets daily for 54 weeks.
- First-in-Humans Study of New Immunotherapy Agent
(Posted: 01/24/2012) - In this first-in-humans clinical trial of interleukin-15 (IL-15), patients with metastatic melanoma or metastatic renal cell cancer who have not benefited from other therapies will be given IL-15 by intravenous injection once a day for 12 days.
- Combining Second-Line Targeted Therapies for Advanced Kidney Cancer
(Posted: 06/14/2011) - The goal of this clinical trial is to determine whether using everolimus and bevacizumab in combination will improve the overall survival of patients with renal cell carcinoma (kidney cancer) whose disease has progressed on approved tyrosine kinase inhibitors.
- Targeting Tumor Metabolism in Papillary Kidney Cancers
(Posted: 12/14/2010) - In this trial, patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cancer that has spread beyond the kidneys will be treated with erlotinib and bevacizumab.
- Targeted Treatment for Advanced Solid Tumors
(Posted: 12/16/2008) - This clinical trial combines the drug dasatinib with the angiogenesis inhibitor bevacizumab for patients with metastatic or unresectable solid tumors.